medpagetoday.com/meetingcov...
This is an important finding. Note that the study size is around 200, but the outcome was consistent across age and gender for those with advanced melanoma.
For patients with advanced BRAF-mutant melanoma, taking a treatment holiday from BRAF/MEK inhibitors (with the goal of forestalling drug resistance instead led to earlier disease progression, a randomized trial found.
In the phase II study of over 200 patients, median progression-free survival (PFS) for those receiving intermittent dosing of dabrafenib (Tafinlar) and trametinib (Mekinist) was 5.5 months, as compared to 9.0 months for patients receiving continuous treatment (HR 1.36, 80% CI 1.10-1.66, P=0.063), reported Alain Algazi, MD, of the University of California San Francisco.
Peace,
Missy
Tafinlar/Mekinist & Opdivo together